CHICAGO, July 17, 2025 (GLOBE NEWSWIRE) — Neurogen Biomarking will present novel data on at-home p-tau 217 testing for Alzheimer’s disease at the upcoming Alzheimer’s Association International Conference® (AAIC) in Toronto, Canada. Chief Scientific Officer, Elisabeth Thijssen, PhD will report the results of a study designed to validate remote collection of blood biomarkers for Alzheimer’s disease and related disorders.
The Neurogen session is highlighted in AAIC’s Featured Research Session (FRS) that debut and discuss innovative and impactful research findings, drawing together multiple studies that share a common focus. AAIC has also designated Neurogen’s presentation a Clinical Pearl for its real-world relevance to dementia diagnosis and care.
Neurogen’s presentation details include:
About Neurogen
Neurogen Biomarking is on a global mission to give everyone equitable access to brain health care. The company offers the first at-home blood biomarker test for phosphorylated (p-tau217) using proprietary blood collection technology and advanced digital cognitive testing with results guided by board-certified neurologists via telehealth. Neurogen’s vision is to deliver accessible technology, actionable insights, and pathways to precision-based proactive care to support early detection and care for Mild Cognitive Impairment (MCI) and dementia associated with Alzheimer’s disease (AD). Neurogen was founded by award-winning neurologist, Dr. Rany Aburashed and is guided by world-renowned brain health experts.
To learn more, visit www.neurogenbiomarking.com or follow us on LinkedIn.
Media Contact:
Reilly Connect for Neurogen Biomarking
Ashley.Biladeau@reillyconnect.com
952.994.4021
mia.joan@reillyconnect.com
872.240 3696
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…